Tom Brady, medical-imaging pitchman

Dave Pearson | | Health Imaging | Policy & Regulations

Fresh off completing his four-game suspension over the “Deflategate” brouhaha, New England Patriots quarterback Tom Brady is out with a new endorsement. And what’s he helping to sell? Healthcare services for Shields Healthcare—the “official MRI provider of the Patriots.”

The first commercial to come of the deal features Brady removing all four of his Super Bowl rings before going in for an MRI.

Boston Business Journal has coverage plus an embed of the ad:

Tom Brady makes appearance in Farrelly-directed commercial

Dave Pearson
Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Related Content

FDA clears AI-assisted CCTA software that assesses plaques for signs of heart disease
University of Missouri Health Care's 7T scanner joins exclusive ACR accreditation club
Radiologist arrested for secretly recording female patient's breasts during imaging
Why cardiac CT adoption remains low among primary care providers
Injuries trigger recall related to tables used during image-guided procedures
New FDA-cleared algorithm could improve fetal anomaly detection on ultrasound

Around the web

Cardiovascular Business
ASE updates recommendations for assessing right heart function in patients with pulmonary hypertension

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.